Laboratories

Department of Renal Replacement Therapy

KEYWORDS

  • complement regulators
  • nephritis
  • C3 glomerulopathy

HEAD

MIZUNO Masashi

Professor

Researchers

LAB MEMBER

Faculty Position Researchers
KIM Hangsoo Lecturer Researchers
FUKUI Sosuke Assistant Professor Researchers
OTOTAKE Satoshi Assistant Professor Researchers

CONTACT

Email iga-ken-d◎t.mail.nagoya-u.ac.jp (Please send a message after replacing "◎" mark with "@" mark. )

OUTLINE

In Japan, number of patients with end-stage kidney disease (ESKD) requiring dialysis has peaked in 2021 and begun to decline gradually due to the aging population and declining birthrate, but still exceeds 340,000. Chronic kidney disease is a serious national disease, and with the average age at onset of dialysis exceeding 71, it is no exaggeration to say that it is one of the most important diseases in Japan, which is becoming an ultra-aging society. Treatment for these patients relies almost entirely on hemodialysis (HD), but its uneven distribution is significant internationally and poses a major medical and economic problem. Kidney transplantation is considered an ideal treatment, but a significant increase in the number of transplants is currently not expected.
In recent years, the concept of peritoneal dialysis (PD)-first, which involves starting from PD in ESKD patients, has been advocated. This approach offers advantages over HD, such as higher satisfaction in ESKD patinets, paticularily aged patients, and the ability to maintain residual kidney function (the ability to maintain urine output for an extended period of time).
However, current challenges facing PD include medical issues such as the decline in peritoneal function and the development of encapsulating peritoneal sclerosis in patients on long-term PD and/or associcated with PD-related peritonitis, as well as challenges within the medical system, such as a lack of education about PD for nephrologists and nurses, a lack of information provided to patients about PD, and a lack of collaboration between local medical institutions.
Since February 2005, as the ""Depaetment of renal replacement therapy (endosed department)"" we have been working to promote tatal renal failure medical care, including PD and kidney transplantation, at Nagoya University and affiliated hospitals, and have also achieved results in basic research on PD-associated complications.
Furthermore, from 2010, based on the education established in the Nagoya area, we have hosted a renal failure and PD education program (BSJNU (Basic & antecessum Scientia Japan at Nagoya University)) for medical professionals from all over the country.

RESEARCH PROJECTS

Peritoneal dialaysis and the complications
Prevention of ESKD
The complement system and the regulation
Complement mediated diaseases such as kidney diseases incluing C3 glomerulopathy and the other inflamatory diseases
Envenomation and kidney injuries

BIBLIOGRAPHY

2025
  1. Kamiya T, Miyasaka Y, Kim H, Fukui S, Inoue M, Ishigami M, Suzuki Y, Maruyama S, Ohno T, Hughes TR, Morgan BP, Mizuno M. Absence of complement terminal pathway activity in C6-deficient mice prolongs survival in a mouse model of severe malarial infection. Immunobiol. 230(6):153140, 2025.
2024
  1. Koshitori Y, Takai N, Isomura Y, Hiramatsu T, Suzuki Y, Kim H, Fukui S, Mizuno M. Delaying treatment for peritonitis could be related to longer hospitalization in patients on peritoneal dialysis. Renal Replacement Therapy 2024, 10:69.
2023
  1. Kamegai N, Kim H, Suzuki Y, Fukui S, Kojima H, Maruyama S, Morgan BP, Zelek WM, Mizuno M. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clin Exp Immunol. 214(2):209-218, 2023
  2. Fukui S, Mizuno M, Tawada M, Suzuki Y, Kojima H, Matsukawa Y, Imai M, Kim H, Kinashi H, Mizutani M, Minoshima K, Maruyama S, Ito Y. Peritoneal expression of membrane complement regulators is decreased in peritoneal dialysis patients with infected peritonitis. Int J Mol Sci. 24; 9146, 2023.
  3. Yamane R, Yasuda Y, Oshima A, Suzuki Y, Kojima H, Kim H, Fukui S, Maruyama S, Ito Y, Mizuno M. Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients. BMC Nephrol. 24:26, 2023.
2022
  1. Kobayashi K, Ozeki T. Kim H, Imai M, Kojima H, Iguchi D, Fukui S, Suzuki M, Suzuki Y, Maruyama S, Ito Y, Mizuno M. Long-term peritoneal dialysate exposure modulates expression of membrane complement regulators in human peritoneal mesothelial cells. Front Med. 9.972592, 2022.
  2. Takagi K, Takahashi H, Miura T, Yamagiwa K, Kawase K, Muramatsu-Maekawa Y, Koie T, Mizuno M. Prognostic value of the Controlling Nutritional Status (CONUT) score in patients at dialysis initiation. Nutrients 14(11):2317,2022.
2021
  1. Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I, Sugiyama H, Fujimoto S, Miura K, Matsumura C, Gotoh Y, Suzuki H, Kuroki A, Yoshino A, Nakatani S, Hiromura K, Yamamoto R, Yokoyama H, Narita I, Isaka Y. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One. 2021 Sep 14;16(9):e0257397.
  2. Ozeki T, Mizuno M, Iguchi D, Kojima H, Kim H, Suzuki Y, Kinashi H, Ishimoto T, Maruyama S, Ito Y. C1 inhibitor mitigates peritoneal injury in zymosan-induced peritonitis. Am J Physiol Renal Physiol. 320:F1123-F1132, 2021.
  3. SuzukiY, Mizuno M, Kojima H, Sato Y, Kim H, Kinashi H, Katsuno T, Maruyama S, Ito Y. Oral antibiotics are effective to prevent colonoscopy-associated peritonitis as a preemptive therapy in patients on peritoneal dialysis. Intern Med. 60(3):353-356, 2021.
  4. Tawada T, Ito Y, Banshodani M, Yamashita M, Shintaku S, Sun T, Suzuki Y, Kinashi H, Kubo Y, Ando M, Yamaguchi M, Katsuno T, Mizuno M, Kawanishi H. Vasculopathy plays an important role during the development and relapse of encapsulating peritoneal sclerosis with conventional peritoneal dialysis solutions. Nephrol Dial Transplant. 36 (8):1519-1526, 2021
2019
  1. Sun T, Sakata F, Ishii T, Tawada M, Suzuki Y, Kinashi H, Katsuno T, Takei Y, Maruyama S, Mizuno M, Ito Y. Excessive salt intake increases peritoneal solute transport rate via local tonicity-responsive enhancer binding protein in subtotal nephrectomized mice. Nephrol Dial Transplant. 34(12):2031-2042, 2019,
  2. Tawada H, Hamada C, Suzuki Y, Sakata F, Sun T, Kinashi H, Katsuno T, Takei Y, Maruyama S, Honda K, Mizuno M, Ito Y. Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients. Clin Exp Nephrol. 23: 689-699, 2019,
2018
  1. Iguchi D, Mizuno M, Suzuki Y, Sakata Y, Maruyama Y, Okada A, Okada H, Ito Y. Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rat pretreated with methylglyoxal. Am J Physiol Renal Physiol. 315: F1732-F1746, 2018.
2017
  1. Mizuno M, Suzuki Y, Higashide K, Sei Y, Iguchi D, Sakata F, Horie M, Maruyama S, Matsuo S, Morgan BP, Ito Y. High level of soluble C5b-9 complex in dialysis fluid is a predictor of poor prognosis in peritonitis in peritoneal dialysis patients. PLosOne 12:e0169111, 2017.
2014
  1. Kim H., Mizuno M., Furuhashi K., Katsuno T., Ozaki T., Yasuda K., Tsuboi N., Sato W., Suzuki Y., Matsuo S., Ito Y., Maruyama S.: Rat adipose tissue-derived stem cells attenuate peritoneal injuries in rat zymosan-induced peritonitis accompanied by complement activation. Cytotherapy 16:357-368, 2014.

Back to top of page